SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that Dr. Susan Billings will join the company as Chief Commercial Officer. In this pivotal role, Susan will lead Resilience’s commercial organization, focusing on brand building, revenue growth and market expansion to deliver exceptional customer-centric solutions across Resilience’s diverse biomanufacturing portfolio..

圣地亚哥--（商业新闻短讯）--National Resilience，Inc.（Resilience），一家专注于技术的生物制造公司，致力于扩大复杂药物的使用范围，今天宣布苏珊·比林斯博士将加入该公司担任首席商务官。在这一关键角色中，Susan将领导Resilience的商业组织，专注于品牌建设、收入增长和市场扩张，在Resilience的多样化生物制造产品组合中提供以客户为中心的卓越解决方案。。

Prior to joining Resilience, Dr. Billings served as the founding Chief Commercial Officer of Vivodyne, a TechBio platform technology start-up, where she established their commercial and corporate strategy for bringing their disruptive platform to market. Prior to that, Susan served as Vice President & Global Head of Business Development at Curia, a multi-national CDMO and led Curia’s global business development teams for drug discovery, development and manufacturing for biologics and small molecules, fine chemicals, and analytical and laboratory testing services.

在加入Resilience之前，比林斯博士曾担任TechBio平台技术初创公司Vivodyne的创始首席商务官，在那里她制定了将颠覆性平台推向市场的商业和企业战略。在此之前，苏珊曾担任多国CDMO Curia的副总裁兼全球业务发展负责人，并领导Curia的全球业务发展团队，负责生物制剂和小分子、精细化学品的药物发现、开发和制造，以及分析和实验室测试服务。

After earning her PhD in organic chemistry from the University of California, Irvine and before Curia, Susan advanced through technical and operational roles at an oncology start-up and then at Merck..

苏珊在加州大学欧文分校获得有机化学博士学位后，在库里亚之前，她先后在一家肿瘤初创公司和默克公司担任技术和运营职务。。

“I am honored to join Resilience at this transformative stage in its growth journey,” said Dr. Billings. “The company’s commitment to advancing biopharmaceutical technology and broadening access to complex medicines resonates deeply with my passion to help clients ensure patients gain access to life-changing medicines.

比林斯博士说：“我很荣幸能在这一变革阶段加入到恢复力的成长之旅中。”。“该公司致力于推进生物制药技术和扩大复杂药物的使用范围，这与我帮助客户确保患者获得改变生命的药物的热情产生了深刻的共鸣。

Throughout my career, I’ve focused on building high-performing commercial teams and fostering strong client relationships. At Resilience, I’m eager to apply my experiences to help drive sustainable growth and strengthen our ability to serve biotech and pharma clients with unrivaled quality and reliability.

在我的职业生涯中，我一直专注于建立高绩效的商业团队和培养强大的客户关系。在Resilience，我渴望应用我的经验来帮助推动可持续增长，并增强我们以无与伦比的质量和可靠性为生物技术和制药客户服务的能力。

Together, we will accelerate commercial momentum for biopharmaceutical manufacturing, positioning Resilience as one of the top development and manufacturing organizations worldwide.”.

。

“We are thrilled to welcome Susan to our team at such a critical time in our company’s evolution,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “Her extensive experience in developing and scaling effective commercial strategies, combined with her innovative mindset, makes her an ideal fit for Resilience as we continue our growth trajectory.

Resilience首席执行官Rahul Singhvi博士表示：“在公司发展的关键时刻，我们很高兴欢迎Susan加入我们的团队。”。。

We are confident that the fresh perspective she brings, along with her strategic vision, will unlock new opportunities for Resilience. We look forward to her leadership in advancing our commercial strategy and achieving our growth objectives.”.

我们相信，她带来的全新视角以及她的战略愿景将为恢复能力开启新的机遇。我们期待着她在推进我们的商业战略和实现我们的增长目标方面发挥领导作用。”。

Dr. Billings is a proven leader that blends her foundational roots in laboratory chemistry, outstanding customer insight and a deep understanding of risk management. She drives leading commercial results serving pharma and biotech customers delivering next generation products and services that improve quality of life.

比林斯博士是一位公认的领导者，她将实验室化学的基础知识、卓越的客户洞察力和对风险管理的深刻理解融为一体。她推动领先的商业成果，为制药和生物技术客户提供下一代产品和服务，提高生活质量。

She brings over 15 years of experience in client-relationship growth and partnership, technology launch, commercial strategy, business integration and transformation, building and scaling high-performance business development teams in dynamic, high-growth environments, including large and small, public and private equity, and VC-backed companies..

她在客户关系增长和合作伙伴关系、技术发布、商业战略、业务整合和转型、在动态、高增长环境中建立和扩展高性能业务开发团队方面拥有超过15年的经验，包括大型和小型、公共和私人股本以及风投支持的公司。。

About Resilience

关于弹性

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell and gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale.

Resilience是一家专注于技术的生物制造公司，致力于扩大复杂药物（生物制剂，疫苗，核酸，细胞和基因治疗方式以及药物产品）的获取。该公司成立于2020年，正在构建一个可持续的高科技端到端制造解决方案网络，以确保能够快速、安全、大规模地进行今天和明天的治疗。

By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit resilience.com/ and follow us: Resilience on LinkedIn..

通过不断推进生物制药制造和开发科学，Resilience寻求让其合作伙伴专注于改善患者生活并保护生物制药供应链免受未来中断的发现。有关更多信息，请访问resility.com/并关注我们：LinkedIn上的resility。。